Mylan Delivers Much-anticipated "One Pill Once a Day" Triple Fixed-dose
Antiretroviral Combination to the South African National Department of Health
JOHANNESBURG and PITTSBURGH, April 16, 2013
JOHANNESBURG and PITTSBURGH, April 16, 2013 /PRNewswire/ --Mylan Inc.
(Nasdaq: MYL) announced that its subsidiary, Mylan Laboratories Ltd., a
leading manufacturer of antiretroviral (ARV) drugs, has delivered, through its
South African-based subsidiary Mylan (Proprietary) Limited (Mylan Limited),
stock of the highly anticipated "one pill once a day" ARV combination to the
South African National Department of Health's Gauteng depot. Mylan was
selected in November 2012 to be one of the leading suppliers of ARV drugs to
the National Department of Health for the tender period January 1, 2013 to
December 31, 2014.
In November 2012, the South African Minister of Health, Dr. Aaron Motsoaledi,
announced that, "As from April next year, patients who are on ARV treatment
will no longer have to take three tablets, but only need one tablet per day."
On April 8, 2013, Dr. Motsoaledi launched the FDC ARVs at Phedisong 4
Community Health Clinic. "From June onwards, all other stable, non-complicated
patients will be switched to FDCs after consultation with their clinicians,"
To support the National Department of Health's commitment to providing this
option to people living with HIV/AIDS in South Africa, Mylan has delivered
stock ahead of the deadline. Additionally, as part of Mylan's efforts to
further consumer education and support anti-counterfeit measures, Mylan has
partnered with TrustaTAG Systems. TrustaTAG Systems developed PharmaTAG™, a
patented system using unique two-dimensional tags that enable consumers to use
their mobile phones to simply scan the TAG on a product and gain access to
patient-information leaflets, pack shots, company information and other items.
The TrustaTAG offering allows for a company to display information in
multiple languages, which in the South Africa context is hugely beneficial.
TrustaTAG™ ensures compliance with the Consumer Protection Act and the
Medicines Act, ensuring that patients receive all necessary information in an
"Availability of the 'one pill once a day' ARV combination is another
important step in the fight against HIV/AIDS in South Africa. Simplifying
treatment options, with the added benefit of reduced pressure on logistics and
supply systems, is the first step towards greater access to those in need of
these life-saving medicines," said Anirudh Deshpande, Head of Emerging Markets
and Exports for Mylan Laboratories Ltd.
Ian Puttergill, CEO of TrustaTAG Systems commented, "We are really excited and
proud to work with a market-leading company such as Mylan, which has shown
incredible drive and passion to provide patients access to vital product
information through innovative channels such as TrustaTAG™."
Mylan supplies ARV drugs to more than 120 countries around the world, and
nearly 40% of HIV/AIDS patients receiving treatment in developing countries
depend on a Mylan ARV product. Mylan recently entered the South African market
with a comprehensive portfolio of ARV drugs, consisting of first- and
second-line adult and pediatric therapies, including several dual and triple
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com
Contact: Nina Devlin (Media), 724.514.1968; Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.